top of page

F.T.C. Slams Middlemen for High Drug Prices, Reversing Hands-Off Approach

Writer's picture: Tex PatientsTex Patients

The Federal Trade Commission sharply criticized pharmacy benefit managers, saying in a scathing 71-page report that “these powerful middlemen may be profiting by inflating drug costs and squeezing Main Street pharmacies.”


The regulator’s study signals a significant ramping up of its scrutiny of benefit managers under the agency’s chair, Lina Khan. It represents a remarkable turnabout for an agency that has long taken a hands-off approach to policing these companies.


2 views0 comments

Comments


TCFP_TX_Logo.png
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn

Paid for by the Texas Coalition for Patients

bottom of page